(Reuters) - Affymetrix Inc estimated third-quarter revenue that was below Wall Street expectations, as tightening academic funding worldwide reduced sales at its gene expression and eBioscience...
We are no longer providing equity research on Affymetrix AFFX . We provide broad coverage of more than 1,700 companies across more than 140 industries and adjust our coverage as necessary based on client demand and investor interest.
(Reuters) - Shares of Affymetrix Inc fell about 20 percent on Thursday, a day after the genetic analysis products maker reported preliminary second-quarter revenue below market expectations.
Affymetrix AFFX swung to profitability in the third ..... needle on our fair value estimate. Affymetrix reported $74 million in sales, 5 ..... cancer research. On the capital front, Affymetrix has continued to repurchase its convertible
Affymetrix AFFX reported second-quarter results with revenue that came within its ..... Diagnostics to launch a colorectal cancer test. These efforts underpin Affymetrix 's efforts to focus investments on validation and diagnostic testing
Affymetrix AFFX today lowered its second-quarter revenue outlook to a range of $71 ..... decline. Lower second-quarter revenue will make it difficult for Affymetrix to achieve our full-year sales projections, and we are considering
ensure its dominance beyond the current technology cycle. For example, the recent downfall of former niche leader Affymetrix AFFX (rating: BB-) reads like a cautionary tale for Illumina creditors. Beyond those high business risks, we think
our issuer credit rating for Affymetrix AFFX at BB - , firmly in junk territory ..... genetic analysis niche , and Affymetrix has become a laggard , falling ..... before . While we still think Affymetrix will be able to sell its diagnostic
Affymetrix AFFX reported first - quarter results in line with our expectations . We will maintain our fair value estimate as we still have worries
Affymetrix AFFX produced a strong fourth quarter, topping our earnings projections and turning a profit. While we have improved our outlook for